CLDN1 and hepatocellular carcinoma: Clement et al. [61] developed a specific CRISPR/Cas9 system that targets Claudin-1 (CLDN1), a major HCV receptor in the hepatocellular carcinoma Huh7.5.1 monoclonal cell line.